

CITATION REPORT

List of articles citing

Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study

DOI: 10.1111/jth.13815

Journal of Thrombosis and Haemostasis, 2017, 15, 2125-2137.

Source: <https://exaly.com/paper-pdf/66973732/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
34	[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine]. <i>Medizinische Klinik - Intensivmedizin Und Notfallmedizin</i> , 2017 , 112, 83-91	3.2	
33	Advances in Stroke 2017. <i>Stroke</i> , 2018 , 49, e174-e199	6.7	19
32	Reversal agents for non-vitamin K antagonist oral anticoagulants. <i>Nature Reviews Cardiology</i> , 2018 , 15, 273-281	14.8	92
31	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018 , 39, 1330-1393	9.5	1094
30	Role of Blood Bank, Transfusion Services, and Pharmacy in ICU Patients with Hematologic Challenges. 2018 , 391-406		
29	The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. <i>International Journal of Emergency Medicine</i> , 2018 , 11, 55	3.9	14
28	International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery. <i>Anaesthesia</i> , 2018 , 73, 1535-1545	6.6	26
27	Andexanet alfa for the treatment of hemorrhage. <i>Expert Review of Hematology</i> , 2018 , 11, 847-855	2.8	2
26	Testing and monitoring direct oral anticoagulants. <i>Blood</i> , 2018 , 132, 2009-2015	2.2	39
25	Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 278-287	6.9	29
24	Transient or extended reversal of apixaban anticoagulation by andexanet[alfa is equally effective in a porcine polytrauma model. <i>British Journal of Anaesthesia</i> , 2019 , 123, 186-195	5.4	8
23	Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1265-1279	6.2	75
22	Andexanet alfa for the reversal of factor Xa inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 387-397	5.4	5
21	Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. <i>Anesthesiology</i> , 2019 , 131, 1153-1165	4.3	8
20	Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage. <i>Stroke</i> , 2019 , 50, 529-536	6.7	15
19	Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban. <i>Acta Haematologica</i> , 2020 , 143, 266-271	2.7	4
18	Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents. <i>Journal of Emergency Medicine</i> , 2020 , 58, 217-233	1.5	7

17	Reply to "Key Points to Consider When Evaluating Andexxa for Formulary Addition". <i>Neurocritical Care</i> , 2020 , 33, 323-326	3.3	
16	Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 1282-1294	5.1	3
15	Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 986-998	5.3	3
14	Drugs, Devices, and Procedural Therapies to Prevent Recurrent Cardiogenic Embolic Stroke. 2020 , 337-383		
13	An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Advances in Hematology</i> , 2020 , 2020, 7636104	1.5	13
12	Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 598-605	2.9	3
11	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021 , 23, 1612-1676	3.9	99
10	Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation. <i>Anesthesiology</i> , 2020 , 133, 223-232	4.3	1
9	Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update. <i>Indian Journal of Anaesthesia</i> , 2019 , 63, 169-181	1.5	11
8	POSSIBILITIES OF INHIBITING ANTICOAGULANT ACTIVITIES THAT INHIBIT XA-FACTOR. <i>Atherothrombosis</i> , 2019 , 72-81	0.3	
7	Bleeding on Anti-Xa Drugs: Does All Bleeding Really Stop? 2020 , 1-17		
6	Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro.. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6, e12699	5.1	
5	Use of Anticoagulants in COVID-19: A Review.. <i>American Journal of Therapeutics</i> , 2022 ,	1	1
4	In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra. 2022 , 6,		
3	DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature. 2023 , 21, 433-452		0
2	Direct Oral Anticoagulants: Laboratory Challenges and Antidotes. 2023 , 43, 037-043		0
1	Optimal Management of the Geriatric Trauma Patient. 2023 , 11, 101-107		0